BioGeneration Ventures (BGV) is a venture capital company, with a focus on early stage European biotech, medtech, and diagnostics companies. BGV has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class teams. The Company manages over €100 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together.
BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realisation for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit.
Historical successful investments include divestment of Dezima Pharma to Amgen for up to USD 1.55 billion in total deal value and in Acerta Pharma for up to USD 7 billion with a guaranteed payment of USD 4 billion. Both companies were co-founded by BGV in 2012 and 2013 respectively. The Acerta Pharma sale was the largest exit ever of a privately held European biotech company.
BGV is based in Naarden, The Netherlands, and closely collaborates with Forbion.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2006
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was BGV (BioGeneration Ventures) founded?
BGV (BioGeneration Ventures) was founded in 2006.
What industry is BGV (BioGeneration Ventures) in?
BGV (BioGeneration Ventures) operates in Venture Capital and Private Equity Principals. Find similar Venture Capital and Private Equity Principals investors on gritt.io.
Where is BGV (BioGeneration Ventures) based?
BGV (BioGeneration Ventures) is headquartered in Naarden, Netherlands.
Find investors for your startup like BGV (BioGeneration Ventures)
Gritt sends AI-personalised outreach to each investor — from your Gmail
